New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
04:55 EDTCRME, CRME, ALR, ALR, GALE, GALE, BIND, BIND, AVNR, AVNR, OCRX, OCRX, ONVO, ONVO, OSIR, OSIR, SGNT, SGNT, SNTA, SNTA, CRIS, CRISJMP Securities to hold a conference
Healthcare Conference to be held in New York on June 24-25.
News For CRME;SNTA;SGNT;OSIR;ONVO;OCRX;AVNR;BIND;GALE;ALR;CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 28, 2014
08:13 EDTAVNRAvanir CRL news for AVP-825 as expected, says JMP Securities
Subscribe for More Information
November 26, 2014
16:57 EDTAVNRAvanir receives CRL from FDA on AVP-825
Subscribe for More Information
07:48 EDTAVNRFDA PDUFA Date for Avanir's AVP-825 is November 26, 2014
Subscribe for More Information
November 25, 2014
14:13 EDTOSIRLegislation an opportunity for Athersys, Osiris says Piper Jaffray
Subscribe for More Information
November 24, 2014
10:32 EDTAVNRDoctors viewing Avanir AVP-923 data favorably, says Deutsche Bank
Subscribe for More Information
November 21, 2014
09:17 EDTGALEOn The Fly: Pre-market Movers
Subscribe for More Information
November 20, 2014
16:22 EDTGALEGalena announces $55M purchase agreement with Lincoln Park Capital
Galena Biopharma announced the execution of a purchase agreement for up to $55M with Lincoln Park Capital Fund, a Chicago-based institutional investor. Under the terms of the purchase agreement dated November 18, LPC initially purchased $5M of Galena common stock at a price of $2.00 per share, 9% higher than the market close as of November 18, 2014. Thereafter, at its sole discretion, Galena may sell up to $50M worth of common stock to LPC over the 36-month term of the purchase agreement, subject to the conditions and limitations set forth in the purchase agreement. Under the terms of the purchase agreement, LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Galena common stock and is obligated to purchase at times and amounts controlled by the company. In consideration for entering into the agreement the company issued shares of its common stock to LPC as a commitment fee. Galena plans to use the proceeds received for its commercial and product development activities and for other working capital and general corporate purposes.
10:33 EDTOSIRHigh option volume stocks
High option volume stocks: KBR LM PRGO CHRW DG ZMH LGF ZTS OSIR REGI
08:43 EDTBINDBIND Therapeutics data encouraging, says JMP Securities
JMP Securities believes that data for BIND's BIND-014 showed encouraging evidence of activity and overall survival in difficult-to-treat subsets of non-small cell lung cancer. The firm reiterates a $30 price target and Outperform rating on BIND.
November 19, 2014
07:44 EDTOCRXStifel to hold a conference
Subscribe for More Information
07:09 EDTALRJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
07:04 EDTSNTASynta Pharmaceuticals presents preclinical results from Hsp90 platform
Synta Pharmaceuticals announced that a poster highlighting preclinical results from its Hsp90 inhibitor Drug Conjugate platform is being presented at the 26th EORTC-NCI-AACR Symposium in Barcelona. “This poster highlights our ongoing evaluation of multiple candidates from the HDC platform. The preclinical results for our lead candidates not only demonstrate broad activity across several tumor types, but also the ability for HDCs to induce prolonged antitumor effects as compared to well-established cytotoxic agents,” said Weiwen Ying, Vice President, Discovery Chemistry at Synta. “In addition, the platform is not limited to using traditional cytotoxic therapeutics as payloads. A number of commonly used small molecule anticancer agents may also be incorporated, including tyrosine kinase inhibitors, proteosome inhibitors, small molecule immunotherapeutics, and other molecularly targeted agents. By leveraging the preferential retention characteristic of the Hsp90 targeting arm of an HDC in tumors, intratumoral exposure and antitumor potency for a wide array of payloads can be potentially improved." "We are encouraged by the progress the team has achieved to date with candidates arising from the HDC platform and the promise that the platform holds for both internal development and partnerships,” said Anne Whitaker, President and CEO of Synta. “We continue to evaluate options for efficiently advancing candidates from this platform and look forward to providing updates in the future.”
07:03 EDTBINDBIND Therapeutics says BIND-014 met primary objective in Phase 2 study
Subscribe for More Information
November 18, 2014
12:08 EDTONVOOn The Fly: Midday Wrap
Subscribe for More Information
08:09 EDTONVOOrganovo announces commercial release of exVive3D liver tissue
Organovo Holdings announced the full commercial release of the exVive3D Human Liver Tissue for preclinical drug discovery testing. Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.
07:37 EDTGALEStifel to hold a conference
Subscribe for More Information
07:20 EDTBINDEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
07:09 EDTGALEGalena completes enrollment in GALE-401 Phase 2 clinical trial
Galena Biopharma announced the completion of enrollment in the GALE-401, or Anagrelide Controlled Release, Phase 2 Clinical Trial. The Phase 2, clinical proof-of-concept study is treating 18 patients with elevated platelet counts in myeloproliferative neoplasms, or MPNs, including Essential Thrombocythemia, or ET, Polycythemia Vera, or PV, and Primary Myelofibrosis, or PMF. The Phase 2 trial is an open-label, single-arm, multicenter study designed to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure plasma concentrations of anagrelide. The platelet lowering ability of GALE-401 will be measured by the proportion of patients that achieve a complete or partial platelet response for at least four weeks during 24 weeks of treatment. With enrollment complete, patients will now be followed for platelet response while they continue study treatment.
November 17, 2014
08:38 EDTCRMECardiome enters commercialization agreement with Aspen for BRINAVESS
Subscribe for More Information
07:20 EDTALRLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use